Disclosure Of Entity's Operating Segments [Text Block]

Hyloris Pharmaceuticals SA - Filing #5880972

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
Disclosure of entity's operating segments [text block]
5
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
8,458,000 EUR
2,087,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method
81,000 EUR
147,000 EUR
Tax expense (income)
- EUR
- EUR
Profit (loss) before tax
6,342,000 EUR
15,380,000 EUR
Profit (loss)
6,342,000 EUR
15,380,000 EUR
Assets
41,335,000 EUR
47,681,000 EUR
Investments accounted for using equity method
2,748,000 EUR
3,801,000 EUR
Liabilities
9,192,000 EUR
8,613,000 EUR
Cash flows from (used in) operating activities
6,903,000 EUR
12,808,000 EUR
Cash flows from (used in) investing activities
259,000 EUR
9,889,000 EUR
Cash flows from (used in) financing activities
168,000 EUR
131,000 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.